MOUNTAIN VIEW, Calif., Aug. 3, 2009 (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq:VVUS), a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products, today announced that it will report financial results for the second quarter ended June 30, 2009 after the NASDAQ Market closes on Tuesday August 11, 2009. The company will conduct a conference call and an audio webcast at 1:30pm PT on the same day.
Date: August 11, 2009
Time: 1:30 PM PT
Listen via Internet: http://ir.vivus.com/
Schedule this webcast into MS-Outlook calendar (click open when prompted):
http://apps.shareholder.com/PNWOutlook/t.aspx?m=38312&k=B0D21469
Toll-free: 877-548-7907
International: 719-325-4848
A webcast replay will be available on the VIVUS web site for 30 days.
VIVUS is a biopharmaceutical company developing innovative, next-generation therapies to address unmet needs in obesity, diabetes and sexual health. The company's lead investigational product in clinical development, Qnexa(tm), is expected to complete Phase 3 clinical trials for the treatment of obesity in 2009. Qnexa is also in Phase 2 clinical development for the treatment of type 2 diabetes. In the area of sexual health, VIVUS is in Phase 3 development with avanafil, its PDE5 inhibitor drug candidate, and in Phase 2 development of Luramist(tm), its drug candidate for the treatment of hypoactive sexual desire disorder (HSDD) in women. MUSE(r) (alprostadil), a first generation therapy for the treatment of ED, is already on the market and generating revenue for VIVUS. For more information about the company, please visit www.vivus.com.
CONTACT: VIVUS, Inc.
Timothy E. Morris
Chief Financial Officer
650-934-5200
The Trout Group
Investor Relations:
Brian Korb
646-378-2923
Pure Communications, Inc.
Public Relations:
Sheryl Seapy
949-608-0841
